The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Raxar     1-cyclopropyl-6-fluoro-5- methyl-7-(3...

Synonyms: Grepafloxacin, CHEMBL583, SureCN34155, AGN-PC-00E1BD, CCRIS 7284, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CCRIS 7284


High impact information on CCRIS 7284


Chemical compound and disease context of CCRIS 7284


Biological context of CCRIS 7284


Anatomical context of CCRIS 7284


Associations of CCRIS 7284 with other chemical compounds


Gene context of CCRIS 7284


Analytical, diagnostic and therapeutic context of CCRIS 7284


  1. Grepafloxacin. Wagstaff, A.J., Balfour, J.A. Drugs (1997) [Pubmed]
  2. In vitro activity of OPC-17116. Neu, H.C., Fang, W., Gu, J.W., Chin, N.X. Antimicrob. Agents Chemother. (1992) [Pubmed]
  3. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Wakebe, H., Imada, T., Yoneda, H., Mukai, F., Ohguro, K., Ohmori, K., Tamaoka, H., Yabuuchi, Y. Antimicrob. Agents Chemother. (1994) [Pubmed]
  4. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Chodosh, S., Lakshminarayan, S., Swarz, H., Breisch, S. Antimicrob. Agents Chemother. (1998) [Pubmed]
  5. Therapy for pneumococcal infection at the millennium: doubts and certainties. Ball, P. Am. J. Med. (1999) [Pubmed]
  6. p38 MAPK associated with stereoselective priming by grepafloxacin on O2- production in neutrophils. Niwa, M., Hotta, K., Kanamori, Y., Kumada, M., Hirota, M., Kozawa, O., Fujimoto, S. Free Radic. Biol. Med. (2004) [Pubmed]
  7. Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. Pfister, M., Zhang, L., Hammarlund-Udenaes, M., Sheiner, L.B., Gerber, C.M., Täuber, M.G., Cottagnoud, P. Antimicrob. Agents Chemother. (2003) [Pubmed]
  8. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Zenilman, J.M., Neumann, T., Patton, M., Reichart, C. Antimicrob. Agents Chemother. (1993) [Pubmed]
  9. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Roblin, P.M., Montalban, G., Hammerschlag, M.R. Antimicrob. Agents Chemother. (1994) [Pubmed]
  10. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results. García, M.T., Pelaz, C., Giménez, M.J., Aguilar, L. Antimicrob. Agents Chemother. (2000) [Pubmed]
  11. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Shultz, T.R., Tapsall, J.W., White, P.A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  12. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Kenny, G.E., Cartwright, F.D. Antimicrob. Agents Chemother. (1993) [Pubmed]
  13. Effect of age and gender on the pharmacokinetics of grepafloxacin. Efthymiopoulos, C., Bramer, S.L., Maroli, A. Clinical pharmacokinetics. (1997) [Pubmed]
  14. Effect of food and gastric pH on the bioavailability of grepafloxacin. Efthymiopoulos, C., Bramer, S.L., Maroli, A. Clinical pharmacokinetics. (1997) [Pubmed]
  15. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Efthymiopoulos, C., Bramer, S.L., Maroli, A. Clinical pharmacokinetics. (1997) [Pubmed]
  16. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Turnidge, J. Drugs (1999) [Pubmed]
  17. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Naruhashi, K., Tamai, I., Inoue, N., Muraoka, H., Sai, Y., Suzuki, N., Tsuji, A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  18. Effects of new quinolones on transepithelial electrical potential difference of tracheal mucosa in vivo. Kanoh, S., Tamaoki, J., Kondo, M., Nagano, Y., Nagai, A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  19. Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116. Tanimura, H., Uchiyama, K., Kashiwagi, H. Drugs (1995) [Pubmed]
  20. Theophylline and warfarin interaction studies with grepafloxacin. Efthymiopoulos, C., Bramer, S.L., Maroli, A., Blum, B. Clinical pharmacokinetics. (1997) [Pubmed]
  21. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. Griggs, D.J., Marona, H., Piddock, L.J. J. Antimicrob. Chemother. (2003) [Pubmed]
  22. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. O'Doherty, B., Dutchman, D.A., Pettit, R., Maroli, A. J. Antimicrob. Chemother. (1997) [Pubmed]
  23. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. Sasabe, H., Kato, Y., Suzuki, T., Itose, M., Miyamoto, G., Sugiyama, Y. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  24. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Lowes, S., Simmons, N.L. Br. J. Pharmacol. (2002) [Pubmed]
  25. Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism. Niwa, M., Kanamori, Y., Hotta, K., Matsuno, H., Kozawa, O., Fujimoto, S., Uematsu, T. J. Antimicrob. Chemother. (2002) [Pubmed]
  26. Effect of grepafloxacin on cytokine production in vitro. Ono, Y., Ohmoto, Y., Ono, K., Sakata, Y., Murata, K. J. Antimicrob. Chemother. (2000) [Pubmed]
  27. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. Stewart, B.A., Johnson, A.P., Woodford, N. J. Med. Microbiol. (1999) [Pubmed]
  28. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Lubasch, A., Keller, I., Borner, K., Koeppe, P., Lode, H. Antimicrob. Agents Chemother. (2000) [Pubmed]
  29. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits. Perez, S., Solans, C., Bregante, M.A., Pinilla, I., García, M.A., Honrubia, F. J. Antimicrob. Chemother. (2002) [Pubmed]
WikiGenes - Universities